Comparative Pharmacology
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus GYNODIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus GYNODIOL.
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL vs GYNODIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethynodiol diacetate is a progestin that suppresses gonadotropin secretion (LH and FSH) via negative feedback on the hypothalamic-pituitary axis, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and increases cervical mucus viscosity, impeding sperm penetration.
Estradiol acts by binding to nuclear estrogen receptors, which modulate gene transcription and lead to the development and maintenance of female reproductive tissues and secondary sexual characteristics. Norethindrone acetate is a progestin that suppresses gonadotropin secretion and induces secretory changes in the endometrium.
1 tablet (1 mg ethynodiol diacetate / 35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days.
1 tablet (ethinylestradiol 0.035 mg/norethisterone 1 mg) orally once daily for 21 days, followed by 7 days of placebo or hormone-free interval.
None Documented
None Documented
Ethynodiol diacetate: 12-14 hours; ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady-state achieved after 3-4 days.
Terminal half-life approximately 24-30 hours; steady-state reached by 5-7 days.
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites). Ethynodiol diacetate is extensively metabolized; less than 1% excreted unchanged.
Renal 50-80% as metabolites and conjugates; biliary/fecal 10-20%; unchanged drug <5%.
Category D/X
Category C
Estrogen
Estrogen